Trygve Holmøy (born 1960) senior consultant, professor and head of clinic. He, along with his co-author, was responsible for the article concept and performed individual literature searches. He drafted the article and has approved the submitted version.
The author has completed the ICMJE form and reports the following conflicts of interest: He has received honoraria from Biogen-Idec, Genzyme, Novartis, Merck Serono, TEVA, and the Norwegian MS Society, and is a member of the steering committee/national coordinator for studies sponsored by Biogen-Idec, Merck Serono, Genzyme and Roche. These positions are unpaid.
Øivind Torkildsen (born 1979) senior consultant and professor. He, along with his co-author, was responsible for the article concept and performed individual literature searches. He revised the manuscript and has approved the submitted version.
The author has completed the ICMJE form and reports the following conflicts of interest: He is a member of advisory boards for Biogen-Idec, Genzyme and Merck Serono and has received lecture honoraria and travel grants from Genzyme, Merck Serono, Novartis and Biogen-Idec.
Department of Neurology
Haukeland University Hospital
and
KG Jebsen Centre for MS research
Clinical Institute 1
University of Bergen
()
1.
O'Gorman C, Lin R, Stankovich J et al. Modelling genetic susceptibility to multiple sclerosis with family data. Neuroepidemiology 2013; 40: 1 – 12. [PubMed] [CrossRef]
Munger KL, Åivo J, Hongell K et al. Vitamin D Status During Pregnancy and Risk of Multiple Sclerosis in Offspring of Women in the Finnish Maternity Cohort. JAMA Neurol 2016; 73: 515 – 9. [PubMed] [CrossRef]
4.
Amato MP, Portaccio E. Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs. CNS Drugs 2015; 29: 207 – 20. [PubMed] [CrossRef]
5.
Roux T, Courtillot C, Debs R et al. Fecundity in women with multiple sclerosis: an observational mono-centric study. J Neurol 2015; 262: 957 – 60. [PubMed] [CrossRef]
6.
Hellwig K. Multiple sclerosis and family planning. Neurodegener Dis Manag 2015; 5 (suppl): 39 – 42. [PubMed] [CrossRef]
7.
Sorensen PS, Koch-Henriksen N, Petersen T et al. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol 2014; 261: 1170 – 7. [PubMed] [CrossRef]
8.
Bove R, Alwan S, Friedman JM et al. Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review. Obstet Gynecol 2014; 124: 1157 – 68. [PubMed] [CrossRef]
9.
Coyle PK. Management of women with multiple sclerosis through pregnancy and after childbirth. Ther Adv Neurol Disorder 2016; 9: 198 – 210. [PubMed] [CrossRef]
10.
Vukusic S, Marignier R. Multiple sclerosis and pregnancy in the 'treatment era'. Nat Rev Neurol 2015; 11: 280 – 9. [PubMed] [CrossRef]
11.
Thiel S, Langer-Gould A, Rockhoff M et al. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult Scler 2016; 22: 801 – 9. [PubMed] [CrossRef]
12.
Herbstritt S, Langer-Gould A, Rockhoff M et al. Glatiramer acetate during early pregnancy: A prospective cohort study. Mult Scler 2016; 22: 810 – 6. [PubMed] [CrossRef]
13.
Hatcher SE, Waubant E, Nourbakhsh B et al. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment. JAMA Neurol 2016; 73: 790 – 4. [PubMed] [CrossRef]
14.
Rasenack M, Derfuss T. Disease activity return after natalizumab cessation in multiple sclerosis. Expert Rev Neurother 2016; 16: 587 – 94. [PubMed] [CrossRef]
Friend S, Richman S, Bloomgren G et al. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol 2016; 16: 150. [PubMed] [CrossRef]
19.
Ebrahimi N, Herbstritt S, Gold R et al. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler 2015; 21: 198 – 205. [PubMed] [CrossRef]
20.
Haghikia A, Langer-Gould A, Rellensmann G et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol 2014; 71: 891 – 5. [PubMed] [CrossRef]
21.
Zhovtis Ryerson L, Frohman TC, Foley J et al. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry 2016; 87: 885 – 9. [PubMed] [CrossRef]
22.
Coles A. Newer therapies for multiple sclerosis. Ann Indian Acad Neurol 2015; 18 (suppl 1): S30 – 4. [PubMed] [CrossRef]
23.
de Flon P, Gunnarsson M, Laurell K et al. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology 2016; 87: 141 – 7. [PubMed] [CrossRef]
24.
Thiel S, Langer-Gould A, Rockhoff M et al. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult Scler 2016; 22: 801 – 9. [PubMed] [CrossRef]
25.
Herbstritt S, Langer-Gould A, Rockhoff M et al. Glatiramer acetate during early pregnancy: A prospective cohort study. Mult Scler 2016; 22: 810 – 6. [PubMed] [CrossRef]
Kieseier BC, Benamor M. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis. Neurol Ther 2014; 3: 133 – 8. [PubMed] [CrossRef]
28.
Queisser-Luft A, Stolz G, Wiesel A et al. Malformations in newborn: results based on 30,940 infants and fetuses from the Mainz congenital birth defect monitoring system (1990 – 1998). Arch Gynecol Obstet 2002; 266: 163 – 7. [PubMed] [CrossRef]
29.
Karlsson G, Francis G, Koren G et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology 2014; 82: 674 – 80. [PubMed] [CrossRef]
30.
Jones B. Multiple sclerosis: Study reinforces need for contraception in women taking fingolimod. Nat Rev Neurol 2014; 10: 125. [PubMed] [CrossRef]
31.
Dahl J, Myhr KM, Daltveit AK et al. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurology 2005; 65: 1961 – 3. [PubMed] [CrossRef]
32.
Hellwig K. Pregnancy in multiple sclerosis. Eur Neurol 2014; 72 (suppl 1): 39 – 42. [PubMed] [CrossRef]
33.
Pakpoor J, Disanto G, Lacey MV et al. Breastfeeding and multiple sclerosis relapses: a meta-analysis. J Neurol 2012; 259: 2246 – 8. [PubMed] [CrossRef]
34.
Hellwig K, Rockhoff M, Herbstritt S et al. Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses. JAMA Neurol 2015; 72: 1132 – 8. [PubMed] [CrossRef]
35.
Hale TW, Siddiqui AA, Baker TE. Transfer of interferon β-1a into human breastmilk. Breastfeed Med 2012; 7: 123 – 5. [PubMed] [CrossRef]
36.
Almas S, Vance J, Baker T et al. Management of Multiple Sclerosis in the Breastfeeding Mother. Mult Scler Int 2016; 2016: 6527458.
37.
Baker TE, Cooper SD, Kessler L et al. Transfer of natalizumab into breast milk in a mother with multiple sclerosis. J Hum Lact 2015; 31: 233 – 6. [PubMed] [CrossRef]
This article was published more than 12 months ago and we have therefore closed it for new comments.
I Tidsskriftet nr. 20 publiserte Holmøy og Torkildsen en oversiktsartikkel om behandling av multippel sklerose i svangerskap og ammeperiode (1). Vi er i hovedsak enige i anbefalingene i artikkelen med et unntak: Vi mener at det ikke er nødvendig å pålegge alle…
Vi takker Holmsen og medarbeidere for responsen på vår artikkel om familieplanlegging , graviditet og amming ved multippel sklerose (MS) (1), der de ganske riktig påpeker at det er holdepunkter for at konsentrasjonen av metylprednisolon i morsmelk ser ut til å…
If you do not see the PDF file or want to save the file, you can right-click on the PDF icon. Select «Save target / file as ...» and then retrieve the PDF file in, for example, Acrobat Reader.
Multippel sklerose, graviditet og amming
02.12.2016I Tidsskriftet nr. 20 publiserte Holmøy og Torkildsen en oversiktsartikkel om behandling av multippel sklerose i svangerskap og ammeperiode (1). Vi er i hovedsak enige i anbefalingene i artikkelen med et unntak: Vi mener at det ikke er nødvendig å pålegge alle…